Introduction
Method
Chemotherapy
Monotherapy
Treatment | ACC | MEC | ADC | ||||
---|---|---|---|---|---|---|---|
Author | Regimen | Nb of patients | Nb of objective responses | Nb of patients | Nb of objective responses | Nb of patients | Nb of objective responses |
Licitra et al
7
|
Cisplatin 100 mg/m² every 3w
|
13
|
2
|
5
|
1
|
5
|
0
|
DeHann et al
9
|
Cisplatin 50–120 mg/m² every 4w
|
10
|
0
|
-
|
-
|
-
|
-
|
Suen et al
13
|
Cisplatin
|
14
|
9
|
-
|
-
|
-
|
-
|
Kaplan et al
14
|
Cisplatin 100 mg/m²
|
17
|
10
|
-
|
-
|
-
|
-
|
Jones et al
40
|
Cisplatin 100 mg/m²
|
2
|
0
|
2
|
1
|
3
|
0
|
Schramm et al
8
|
Cisplatin 80-100 mg/m² every 4–6 w
|
10
|
7
|
-
|
-
|
-
|
-
|
Mattox et al
10
|
Mitoxantrone 12 mg/m² every 3w
|
18
|
1
|
-
|
-
|
-
|
-
|
Verweij et al
11
|
Mitoxantrone 14 mg/m² every 3w
|
32
|
4
|
-
|
-
|
-
|
-
|
Vermoken et al
12
|
Epirubicin 30 mg/m² weekly, if no response, 90 mg/m² every 3 w.
|
20
|
2
|
-
|
-
|
-
|
-
|
Suen et al
13
, Kaplan et al
14
|
Doxorubicin (various schema)
|
7
|
3
|
-
|
-
|
-
|
-
|
Airoldi et al
15
|
Vinorelbine 30 mg/m² weekly
|
13
|
2
|
-
|
-
|
5
|
2
|
Spiers et al
16
Tannock et al
17
|
Cyclophosphamide 100 mg/m² every 3 w
|
7
|
0
|
0
|
0
|
0
|
0
|
Tannock et al
17
, Suen et al
13
, Kaplan et al
14
|
5-Fluorouracil (various schema)
|
38
|
16
|
-
|
-
|
-
|
-
|
Tannock et al
17
, Suen et al
13
, Kaplan et al
14
|
Methotrexate (various schema)
|
10
|
0
|
5
|
2
|
1
|
0
|
Gilbert et al
18
|
Paclitaxel 200 mg/m² every 3 w.
|
14
|
0
|
14
|
3
|
17
|
5
|
Raguse et al
19
|
Docetaxel 100 mg/m² every 3 w
|
-
|
-
|
4
|
4
|
-
|
-
|
Van Herpen et al
21
|
Gemcitabine 1250 mg/m² d1 and d8 every 3 w.
|
21
|
0
|
-
|
-
|
-
|
-
|
Cisplatin
Mitoxantrone
Epirubicin
Vinorelbin
Cyclophosphamide
5-Fluorouracil
Methotrexate
Paclitaxel
Docetaxel
Gemcitabin
Polychemotherapy
Treatment | Adenoid cystic carcinoma | Mucoepidermoid carcinoma | Adenocarcinoma | ||||
---|---|---|---|---|---|---|---|
Author | Regimen | Nb of patients | Nb of objective responses | Nb of patients | Nb of objective responses | Nb of patients | Nb of objective responses |
Kaplan et al
14
|
C :200 mg/m² d3-d6 A :40 mg/m² d1 P:50-100 mg/m² d1 every 4 w.
|
-
|
-
|
2
|
1
|
4
|
4
|
Alberts et al
22
|
C :200 mg/m² d3-d6 A :40 mg/m² d1 P :50 mg/m² d1 every 4 w.
|
-
|
-
|
-
|
-
|
3
|
3
|
Dreyfuss et al
23
|
C : 500 mg/m² d1 A :50 mg/m² d1 P : 50 mg/m² d1 every 4w.
|
9
|
3
|
-
|
-
|
4
|
3
|
Belani et al
24
|
C : 400 mg/m² d1 A: 40 mg/m² d1 P : 60 mg/m² d1 every 3–5 w.
|
4
|
1
|
3
|
3
|
1
|
1
|
Creagan et al
25
|
CAP (various schema)
|
11
|
2
|
7
|
2
|
14
|
7
|
Licitra et al
26
|
C: 500 mg/m² d1 A: 50 mg/m² d1 P: 50 mg/m² d1 every 3w.
|
12
|
3
|
1
|
0
|
2
|
0
|
Eisenberg et al
27
|
CAP(not mentioned)
|
0
|
0
|
3
|
2
|
1
|
1
|
Venook et al
28
|
P :50 mg/m² A :30 mg/m² F :500 mg/m² all days1,8 every 4 weeks
|
9
|
3
|
4
|
2
|
3
|
2
|
Dimery et al
29
|
C :500 mg/m² d1 A :50 mg/m² d1 P:40 mg/m² d2d3 F:500 mg/m² d1d2 every 3–4 w.
|
7
|
3
|
1
|
1
|
9
|
4
|
Airoldi et al
30
|
P :60 mg/m² d1 E :50 mg/m² d1 F :600 mg/m² d1 every 3 w.
|
4
|
2
|
-
|
-
|
2
|
1
|
Ross et al
31
|
P :60 mg/m² d1 E :50 mg/m² d1 F :200 mg/m² d1 every 3 w.
|
8
|
1
|
-
|
-
|
-
|
-
|
Tsukuda et al
32
|
C :400 mg/m² d1 Pr :40 mg/m² d1 P :60 mg/m² d1 every 4 weeks
|
6
|
2
|
-
|
-
|
8
|
3
|
Kaplan et al
14
|
C:200 mg/m² d3-d6 A:40-60 mg/m² d1 every 3 w.
|
5
|
2
|
3
|
0
|
3
|
1
|
Posner et al
33
|
C :450 mg/m² d1 A :45mh/m² d1 every 3w
|
5
|
2
|
3
|
0
|
-
|
-
|
DeHaan et al
9
|
P:20 mg/m² d1-d5 A:50 mg/m² d1 B :30 mg d1-d5 every 3w.
|
9
|
3
|
-
|
-
|
-
|
-
|
Triozzi et al
34
|
C :1000 mg/m² d1 Vn :1 mg d1,d4 F :750 mg/m² d1-d4 every 4w.
|
8
|
2
|
-
|
-
|
-
|
-
|
Hill et al
35
|
P :100 mg/m² d1 F :1 g/m² d1-d4 every 4w.
|
11
|
0
|
-
|
-
|
-
|
-
|
Airoldi et al
15
|
P:80 mg/m² d1 V:25 mg/m² d1d8 every 3 w.
|
9
|
4
|
1
|
0
|
4
|
3
|
Airoldi et al
36
|
Cb:AUC5 d1 T :175 mg/m² d1 every 3w.
|
10
|
2
|
1
|
0
|
1
|
0
|
Ruzich et al
37
|
Cb :AUC6 d1 T :200 mg/m² d1 every 3w.
|
-
|
-
|
-
|
-
|
1
|
1
|
Gedlicka et al
38
|
P :30 mg/m² d1-d3 M:12 mg/m² d1 every 3w.
|
11
|
1
|
-
|
-
|
-
|
-
|
Laurie et al
39
|
G :1000 mg/m² d1d8 P : 70 mg/m² d2 or Cb : AUC5 d1 every 3w.
|
10
|
2
|
4
|
1
|
8
|
3
|
Posner et al
33
|
P:20 mg/m² d1-d5 B:10 mg/m² d3-d7 Mtx : 200 mg/m² d14d21 every 3w.
|
-
|
-
|
3
|
2
|
-
|
-
|
Kaplan et al
14
|
P :80 mg/m² d1 B :10 mg/m² d1 Mtx : 40-60 mg/m² d1
|
2
|
0
|
1
|
0
|
-
|
-
|
Jones et al
40
|
E :75 mg/m² d1 F :100 mg/m² d1 every 3w
|
3
|
0
|
1
|
0
|
3
|
0
|
Pedani et al
41
|
P:60 mg/m² d1 I:60 mg/m² d1d8 every 3 w
|
10
|
1
|
1
|
0
|
1
|
0
|
CAP (Cyclophosphamide/Doxorubicin/Cisplatin)
PAF (Cisplatin/Doxorubicin/5FU)
CAPF (Cyclophosphamide/Doxorubicin/Cisplatin/5FU)
PEF (Cisplatin/Epirubicin/5FU)
CPPr (Cyclophosphamide/Cisplatin/Pirabucin)
CA (Cyclophosphamide/Doxorubicin)
PAB (Cisplatin/Doxorubicin/Bleomycin)
CFVn (Cyclophosphamide/5FU/Vincristin)
PF (Cisplatin/5FU)
PV (Cisplatin/Vinorelbine)
PT (Carboplatin/Paclitaxel)
PM (Cisplatin/Mitoxantrone)
GP (Gemcitabin/Cisplatin)
EF (Epirubicin/5FU)
PBMtx (Cisplatin/Bleomycin/Methotrexate)
PI (Cisplatin/Irinotecan)
Targeted therapy
Treatment | Adenoid cystic carcinoma | Mucoepidermoid carcinoma | Adenocarcinoma | ||||
---|---|---|---|---|---|---|---|
Author | Regimen | Nb of patients | Nb of objective responses | Nb of patients | Nb of objective responses | Nb of patients | Nb of objective responses |
Guigay et al
49
|
Imatinib 400 mg twice daily
|
17
|
2
|
-
|
-
|
-
|
-
|
Slevin et al
50
|
Imatinib 800 mg daily for 2 months, if stable disease: P 80 mg/m² every 3w + Imatinib 400 mg daily
|
18
|
0
|
-
|
-
|
-
|
-
|
Ochel et al
51
|
Imatinib 400 mg daily
|
4
|
0
|
-
|
-
|
-
|
-
|
Lin et al
52
|
Imatinib 400 mg twice daily
|
5
|
0
|
-
|
-
|
-
|
-
|
Hotte et al
53
|
Imatinib 40 mg twice daily
|
16
|
0
|
-
|
-
|
-
|
-
|
Pfeffer et al
54
|
Imatinib 400 mg daily, with possible escalation to 800 mg
|
10
|
0
|
-
|
-
|
-
|
-
|
Alcedo et al
55
|
Imatinib 400-600 mg daily
|
2
|
2
|
-
|
-
|
-
|
-
|
Faivre et al
56
|
Imatinib 800 mg daily
|
8
|
0
|
-
|
-
|
-
|
-
|
Glisson et al
58
|
Gefitinib 250 mg daily
|
19
|
0
|
2
|
0
|
3
|
0
|
Agulnik et al
59
|
Lapatinib 1500 mg daily
|
19
|
0
|
2
|
0
|
7
|
0
|
Locati et al
60
|
Cetuximab 400 mg/m² loading dose, then 250 mg/m² weekly.
|
23
|
0
|
2
|
0
|
1
|
0
|
Haddad et al
77
|
Trastuzumab: 4 mg/kg loading dose, then 2 mg/kg weekly.
|
2
|
0
|
3
|
1
|
7
|
0
|
Argiris et al
83
|
Bortezomib 1.3 mg/m² days 1,4,8,11 every 3 weeks. At progression: doxorubicin 20 mg/m² days 1,8.
|
25
|
0
|
-
|
-
|
-
|
-
|